Neumedicines Names Financial Veteran David L. Morash Chief Financial Officer and Director

  Neumedicines Names Financial Veteran David L. Morash Chief Financial Officer
  and Director

Business Wire

PASADENA, Calif. -- March 6, 2013

Neumedicines Inc., a privately held company developing therapies based on
interleukin-12 (IL-12) as a radiation countermeasure and for the treatment of
chemotherapy-induced thrombocytopenia, announces the appointment of David L.
Morash to the newly created position of Chief Financial Officer and as a
member of the company’s Board of Directors, expanding Board membership to
four. Mr. Morash has served as a consultant to the company since 2012, and
brings to Neumedicines more than 30 years of executive-level financial and
executive experience.

“David is a highly experienced executive with extensive financial, strategic
and corporate governance experience. He joins Neumedicines at an important
time in our company’s development as we make preparations to initiate clinical
testing with HemaMax™ (rHuIL-12) in two cancer indications and expect to
receive additional funding from the U.S. Government’s Biomedical Advanced
Research & Development Authority (BARDA) to continue development of HemaMax™
as a biodefense radiation medical countermeasure,” said Lena Basile, J.D.,
Ph.D., President and Chief Executive Officer of Neumedicines. “We look forward
to David’s contributions as we advance our business plan, and welcome him to
our company and our Board.”

“I’m delighted to join the team at Neumedicines in working to develop and
maximize the vast potential of HemaMax™,” said Mr. Morash. “This is indeed an
exciting opportunity as Neumedicines prepares to enter a new phase in its
corporate development.”

Most recently Mr. Morash was Chief Financial Officer of ISE Corporation, where
he was instrumental in several fundraises and in preparing the company for an
initial public offering. Prior to ISE, he served as President, Chief Operating
Officer and Chief Financial Officer of publicly traded Axesstel, Inc., which
he helped to take public. He also served as Executive Vice President and Chief
Financial Officer of publicly traded Remec. Earlier in his career, he was
Executive Vice President of Wireless Knowledge, a joint venture between
Qualcomm and Microsoft, and Executive Vice President and Chief Financial
Officer of Safeskin Corporation, a medical device company rated by Forbes as
the Best Small Company in the U.S.

Mr. Morash serves on the Board of Directors of California Safe Soil, LLC, a
privately held San Diego-based company he co-founded. He holds BA and MBA
degrees from Columbia University.

About Neumedicines Inc.

Neumedicines Inc. is developing protein therapeutics that address unmet
clinical and societal needs in the fields of oncology, hematology and
immunology. The company’s lead product candidate is HemaMax™ (recombinant
human interleukin-12, or rHuIL-12), which functions by targeting multiple
pathways of hematopoiesis and innate immunity. HemaMax™ is being development
as a biodefense radiation medical countermeasure and for indications in
oncology, initially for chemotherapy-induced thrombocytopenia. Neumedicines is
committed to developing and maximizing the scientific, clinical and commercial
potential of its product pipeline. For more information, please visit
www.neumedicines.com or follow the Company on Twitter @Neumedicines.

Contact:

At the Company:
Neumedicines Inc.
David Morash, CFO
626-844-3800
dmorash@neumedicines.com
or
Investor Contact:
LHA
Jody Cain
310-691-7107
Jcain@lhai.com
 
Press spacebar to pause and continue. Press esc to stop.